Cirrhosis

Etiology and Risk Factors

Cirrhosis is the common structural endpoint of diverse chronic insults, including viral hepatitis, alcohol-associated injury, metabolic dysfunction-associated steatohepatitis, and autoimmune, cholestatic, or inherited diseases (Mukhtar & Khalili, 2019).

Epidemiology and Clinical Context

Population context: Mixed etiologies are possible; the absence of a history of heavy alcohol intake does not make clinically significant fibrosis unlikely (Mukhtar & Khalili, 2019).

Pathophysiology

Fibrosis causes both vascular and functional disease

Repeated hepatic injury activates stellate cells and promotes collagen deposition around sinusoids and portal structures. Regenerative nodules and scarring distort the normally low-resistance sinusoidal network. Portal pressure rises; blood bypasses hepatocytes via collateral vessels. Simultaneously, loss of hepatocyte mass and impaired perfusion reduce albumin synthesis, coagulation-factor production, bilirubin processing, metabolic homeostasis, and detoxification. Fibrosis may regress with treatment of the underlying cause in selected patients, but established portal hypertensive complications require their own management (Baveno VIII Faculty, 2026; Mukhtar & Khalili, 2019).

Ascites: explain the paradox of fluid overload with poor renal perfusion

Elevated sinusoidal pressure increases fluid delivery to the peritoneal space, while splanchnic arterial vasodilation lowers effective arterial volume. Renin–angiotensin–aldosterone activation and sympathetic responses retain sodium and water. Reduced albumin may contribute, but ascites is not explained by hypoalbuminemia alone. A serum–ascites albumin gradient (SAAG) of at least 1.1 g/dL supports portal hypertension as the mechanism; it does not, by itself, identify cirrhosis as the only cause (Biggins et al., 2021; Mukhtar & Khalili, 2019).

Clinical Manifestations

Compensated versus decompensated cirrhosis

Compensated cirrhosis means the patient has not developed the major decompensating events. New ascites, overt hepatic encephalopathy, or variceal hemorrhage marks an important prognostic change. Use clinical findings, imaging/elastography, platelet count and etiology testing to support diagnosis and staging. Child-Pugh and MELD-related measures may inform prognosis and transplant prioritization but do not replace direct assessment of infection, bleeding, renal injury or instability.

Diagnostic Evaluation

Separate compensation, prognostic stage and surveillance eligibility

Compensated cirrhosis may have few symptoms despite portal hypertension. Development of ascites, overt encephalopathy or variceal hemorrhage marks clinical decompensation; worsening renal function or infection may accelerate prognosis even without dramatic aminotransferase changes. Child-Pugh groups albumin, bilirubin, INR, ascites and encephalopathy; MELD-based scores use objective laboratory inputs to estimate short-term risk and inform transplant prioritization. Scores are not interchangeable and neither replaces immediate response to an acute complication (American Association for the Study of Liver Diseases & Infectious Diseases Society of America, 2025; Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Perform diagnostic paracentesis for new-onset ascites accessible for sampling, including ascitic albumin, protein, polymorphonuclear cell count, and culture when indicated. In a patient with cirrhosis and ascites who is admitted emergently, obtain diagnostic paracentesis to assess for spontaneous bacterial peritonitis (SBP) even without fever or abdominal pain. The same urgency applies with new encephalopathy, renal deterioration, or other infection findings. An ascitic polymorphonuclear leukocyte count of at least 250 cells/mm³ supports SBP even when cultures are negative; treatment should not await positive culture. Management may include sodium reduction, carefully monitored diuretics, therapeutic paracentesis with albumin when indicated, and selected TIPS or transplant evaluation (Biggins et al., 2021).

Expected Findings

Physiologic failure	Mechanistic link	Clinical consequence
Increased intrahepatic resistance	Fibrosis and nodules obstruct portal flow; portosystemic collaterals form.	Gastroesophageal varices, portal hypertensive gastropathy, splenomegaly and thrombocytopenia.
Splanchnic vasodilation and effective arterial underfilling	Neurohormonal activation increases renal sodium/water retention despite total-body fluid excess.	Ascites, dilutional hyponatremia and susceptibility to kidney dysfunction.
Reduced hepatocyte synthesis/excretion	Albumin and clotting-factor synthesis falls; bilirubin handling declines.	Edema, prolonged INR and jaundice; altered hemostasis is not equivalent to simple anticoagulation.
Reduced detoxification and vascular shunting	Gut-derived neurotoxins and inflammatory signals reach systemic circulation.	Hepatic encephalopathy, especially after infection, bleeding or constipation.
Reduced physiologic reserve	Acute stressors exceed diminished capacity.	Rapid decompensation with infection, hypovolemia, bleeding or drug toxicity.

Differential Diagnosis

Hepatic encephalopathy and hepatorenal physiology

Hepatic encephalopathy results from impaired clearance, portosystemic shunting and neuroinflammation; it is identified clinically, not by ammonia concentration alone. Assess precipitants, including GI hemorrhage, infection, constipation, sedatives, volume depletion and electrolyte derangement. Treatment principles and safety trade-offs are detailed on the decompensation page.

HRS-AKI reflects advanced circulatory dysfunction and renal vasoconstriction, but rising creatinine may instead reflect bleeding, infection, nephrotoxins or tubular injury. These causes must be investigated together. The decompensation page addresses acute AKI differentiation, diagnostic uncertainty, vasoconstrictor risks and escalation.

Treatment and Management

Portal hypertensive bleeding and prevention

Portal hypertension recruits fragile gastroesophageal collaterals that can bleed catastrophically. In compensated cirrhosis with clinically significant portal hypertension, nonselective beta blockers, particularly carvedilol, can prevent decompensation. When beta blockers are contraindicated or not tolerated, endoscopic variceal ligation is recommended for high-risk esophageal varices to prevent a first bleed; ligation alone does not prevent nonbleeding decompensation. Suspected active variceal bleeding requires immediate inpatient stabilization and source control. The vasoactive, antimicrobial, endoscopic and TIPS pathways are addressed on the decompensated cirrhosis companion page (Baveno VIII Faculty, 2026; Tapper et al., 2026).

Longitudinal management and risk reduction

• Address the underlying etiology (viral hepatitis, alcohol-associated injury, metabolic liver disease, autoimmune or cholestatic disease), because halting injury can improve prognosis and sometimes fibrosis (Baveno VIII Faculty, 2026).
• Evaluate nutrition, sarcopenia, sodium and fluid balance, renal function, medication risks, vaccination status, and osteoporosis where indicated. Avoid simplistic protein restriction in hepatic encephalopathy; muscle preservation matters to ammonia handling and outcomes. Provide individualized dietitian-supported nutrition and review immunization needs, including hepatitis A and B immunity and vaccination when indicated (Tapper et al., 2026).
• Provide appropriate hepatocellular carcinoma surveillance and assess the need for variceal prophylaxis. Surveillance remains important in cirrhosis even after cure or control of the original liver disease.
• Refer for transplant evaluation when decompensation, impaired function or prognostic risk warrants it. Acute bleeding, infection, AKI and encephalopathy should trigger reassessment of candidacy and goals of care.

Primary prevention without duplicating emergency pathways

Compensated cirrhosis management includes cause-directed treatment, assessment for clinically significant portal hypertension and first-bleed prevention where indicated. For patients who are candidates for HCC-directed treatment, the 2023 AASLD guidance recommends ultrasound plus alpha-fetoprotein surveillance approximately every six months; technical limitations of ultrasound or markedly limited treatment eligibility may change the surveillance strategy. Variceal prevention and cancer surveillance address different consequences of cirrhosis and should not be conflated (Singal et al., 2023; Tapper et al., 2026).

Complications and Red Flags

High-stakes decompensation patterns

Finding	Mechanism / differential	Immediate clinical priority
Hematemesis, melena, hypotension	Ruptured portal hypertensive varix possible, but peptic ulcer and other sources also occur.	Resuscitate, protect airway as indicated, initiate appropriate vasoactive therapy and antibiotic prophylaxis for suspected variceal bleed, arrange urgent endoscopy and source control.
New confusion, somnolence, asterixis	Encephalopathy may be precipitated by GI bleeding, infection, constipation, dehydration, sedatives or electrolyte abnormalities.	Assess airway and glucose, seek reversible precipitant; exclude stroke, sepsis, intoxication and other causes of altered mental status.
Fever, abdominal discomfort or unexplained renal decline with ascites	SBP or other infection; sometimes few abdominal symptoms.	Prompt diagnostic paracentesis, cultures and empiric treatment when indicated.
Oliguria or rising creatinine	Hypovolemia, sepsis-associated AKI, drug injury, obstruction, intrinsic kidney disease or HRS-AKI.	Assess hemodynamics, urine/medications and infection; do not label every AKI as hepatorenal syndrome.
Increasing abdominal distension or tense ascites	Tense or refractory ascites from fluid accumulation and renal sodium retention.	Evaluate respiratory status and renal/electrolyte function; consider therapeutic paracentesis and specialist input.

Clinical Reasoning Priorities

An adult with known cirrhosis presents with progressive abdominal distension, melena, disorientation and falling urine output. These findings may reflect portal hypertensive bleeding, intravascular depletion despite ascites, infection-triggered encephalopathy and acute kidney injury occurring together. The priority is not to choose one diagnosis prematurely: stabilize bleeding and perfusion, assess mental status and glucose, investigate infection including diagnostic paracentesis, evaluate kidney injury, and obtain urgent multidisciplinary care. The severity is defined by organ dysfunction, not by AST/ALT alone.

---

---

References

American Association for the Study of Liver Diseases & Infectious Diseases Society of America. (2025, January 5). Table 4. Child-Turcotte-Pugh (CTP) classification of cirrhosis severity. HCV Guidance. https://www.hcvguidelines.org/guidance/methods/table-4-child-turcotte-pugh-ctp-classification-of-cirrhosis-severity/

Baveno VIII Faculty. (2026). Baveno VIII—Advancing consensus in portal hypertension. Journal of Hepatology, 85, 993–1018. https://doi.org/10.1016/j.jhep.2026.07.030

Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 74(2), 1014–1048. https://doi.org/10.1002/hep.31884

Mukhtar, N. A., & Khalili, M. (2019). Liver disease. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 14). McGraw-Hill Education.

Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H. (2023). AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 78(6), 1922–1965. https://doi.org/10.1097/HEP.0000000000000466

Tapper, E. B., Kardashian, A., Debes, J. D., Gripshover, J., Moon, A. M., Kim, J. J., & Lai, J. C. (2026). ACG clinical guideline: Preventive care for patients with cirrhosis. The American Journal of Gastroenterology. Advance online publication. https://doi.org/10.14309/ajg.0000000000004186

Williams, M. J., & Gordon-Walker, T. T. (2023). Hepatology. In I. D. Penman, S. H. Ralston, M. W. J. Strachan, & R. P. Hobson (Eds.), Davidson’s principles and practice of medicine (24th ed., pp. 859–920). Elsevier.